[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
OBJECTIVE
The therapeutic effect on melanoma metastasizing to liver is poor. Researches have demonstrated that hepatic intra-arterial bio-chemotherapy can improve the treatment efficacy of metastatic melanoma. This study was to investigate hepatic intra-arterial bio-chemotherapy for the treatment and survival of patients with liver metastasis from melanoma.


METHODS
Twenty-one patients with liver metastasis from melanoma were treated with hepatic intra-arterial infusion of dacarbazine (250 mg/m(2)) from the first to the fifth day, and fotemustine (100 mg/m(2)) at the sixth and fourteenth day, followed by adoptive transfer of autologous cytokine-induced killer cells and administration of interleukin-2 and 150 ug granulocyte/macrophage colony stimulating factor for 10-12 days. The treatment was repeated every 28 days. The overall survival, response and toxicity were analyzed.


RESULTS
Seventeen of twenty-one patients were evaluable. One achieved complete remission (CR), one achieved partial remission (PR), six had stable disease (SD) and nine had progression disease (PD).The disease control rate was 47.06% (8/17), with a median progression free survival (PFS) of 3.76 months and a medium overall survival (OS) of 6 months. Treatment related complications were mainly myelosuppression (grade III-IV), occurring in 38.1% (8/21) patients.


CONCLUSIONS
Hepatic intra-arterial chemotherapy can improve the disease control rate of progressive melanoma. It tends to prolong the PFS and OS with tolerable toxicity in patients with liver metastasis from melanoma.
Cui
Chuan-Liang
CL
Department of Melanoma and Renal Cancer, School of Clinical Oncology, Peking University, Beijing Tumor Hospital, Beijing Institute for Cancer Research, Beijing, P. R. China.
Chi
Zhi-Hong
ZH
Yuan
Xiang-Qing
XQ
Lian
Hong-Yun
HY
Si
Lu
L
Guo
Jun
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055612:Cytokine-Induced Killer Cells / Q000637:transplantation; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006499:Hepatic Artery; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007261:Infusions, Intra-Arterial; D007376:Interleukin-2 / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects; D011994:Recombinant Proteins; D012074:Remission Induction; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D055815:Young Adult
D007376:Interleukin-2; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D011994:Recombinant Proteins; D003606:Dacarbazine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C054368:fotemustine